Education
About Us
Working with TipRanks
Follow Us
Oxford BioDynamics PLC (GB:OBD)
LSE:OBD
OBD Stock Chart & Stats
0.24p
0.04p(3.63%)
At close: 4:00 PM EST
0.24p
0.04p(3.63%)
Day’s Range― - ―
52-Week Range0.20p - 0.78p
Previous CloseN/A
Volume22.58K
Average Volume (3M)21.87M
Market Cap
£12.87M
Enterprise Value10.11M
Total Cash (Recent Filing)£1.39M
Total Debt (Recent Filing)£5.11M
Price to Earnings (P/E)―
Beta-0.84
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,290,911,000
10 Day Avg. Volume50,883,470
30 Day Avg. Volume21,870,725
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.90
Price to Sales (P/S)6.02
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary EpiSwitch PlatformA proprietary, platform-based technology creates a durable competitive advantage: EpiSwitch can be licensed, embedded in multiple diagnostic applications, and reused across programs. Platform-driven IP supports recurring revenue streams, partner integration, and scalable clinical adoption over months to years.
Diverse Revenue Streams & PartnershipsMultiple commercial channels—contract research, licensing and potential royalties—reduce single-pillar dependency and provide complementary cash inflows. Academic and industry collaborations deepen R&D pipeline and create durable deal-flow and co-development pathways that support sustainable commercialization.
High Reported Revenue GrowthElevated revenue growth indicates expanding adoption of services and platform capabilities, demonstrating market demand. Sustained top-line expansion provides the operational runway to scale lab capacity, justify further investment in assays, and offers a pathway to improve margins if growth persists over the coming quarters.
Bears Say
High Financial LeverageVery high debt-to-equity (4.58) materially constrains financial flexibility: servicing debt can divert cash from R&D and commercialization, increase refinancing risk, and amplify downside in adverse conditions. Over a 2–6 month horizon this magnifies funding vulnerability and strategic constraint.
Persistent Negative MarginsNegative gross and EBIT margins point to structural cost or pricing issues rather than one-off items. Continued unprofitable unit economics undermine the ability to self-fund growth and suggest that scaling without margin improvement will perpetuate losses and pressure shareholder returns over the medium term.
Deteriorating Free Cash FlowSharp negative FCF growth and negative operating cash flow versus income indicate the company is burning cash faster, increasing likelihood of external financing. This raises dilution or refinancing risk, constrains investments in commercialization, and threatens runway within a multi-quarter time frame.
Oxford BioDynamics News
OBD FAQ
What was Oxford BioDynamics PLC’s price range in the past 12 months?
Oxford BioDynamics PLC lowest share price was 0.20p and its highest was 0.78p in the past 12 months.
What is Oxford BioDynamics PLC’s market cap?
Oxford BioDynamics PLC’s market cap is £12.87M.
When is Oxford BioDynamics PLC’s upcoming earnings report date?
Oxford BioDynamics PLC’s upcoming earnings report date is Jun 02, 2026 which is in 106 days.
How were Oxford BioDynamics PLC’s earnings last quarter?
Currently, no data Available
Is Oxford BioDynamics PLC overvalued?
According to Wall Street analysts Oxford BioDynamics PLC’s price is currently Overvalued.
Does Oxford BioDynamics PLC pay dividends?
Oxford BioDynamics PLC does not currently pay dividends.
What is Oxford BioDynamics PLC’s EPS estimate?
Oxford BioDynamics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioDynamics PLC have?
Oxford BioDynamics PLC has 4,290,911,000 shares outstanding.
What happened to Oxford BioDynamics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oxford BioDynamics PLC?
Currently, no hedge funds are holding shares in GB:OBD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxford BioDynamics PLC
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Technical Analysis
IXICO plc
―
SkinBioTherapeutics
―
Fusion Antibodies Plc
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---